Literature DB >> 17417738

Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.

T Müller1, D Woitalla, H Russ, K Hock, D A Haeger.   

Abstract

A study into the prevalence and treatment of dyskinesia in Parkinson's disease (PD) patients was performed with 380 PD specialists' completed interviews relating to PD and retrospectively completed 1900 patient record forms for patients with dyskinesia. Physicians reported, that 34% of their PD patients experience dyskinesia, 57% of dyskinetic PD patients were affected by moderately-to-completely disabling dyskinesia. Treatment of dyskinesia was looked upon as not satisfactory, fractionating of levodopa dose was used as first choice therapeutic option of dyskinesia.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17417738     DOI： 10.1007/s00702-007-0718-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  8 in total

1.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

Authors:  A Schrag; N Quinn
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

Review 2.  An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

Authors:  C W Olanow; R L Watts; W C Koller
Journal:  Neurology       Date:  2001-06       Impact factor: 9.910

3.  Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

Authors:  J E Ahlskog; M D Muenter
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

4.  Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.

Authors:  Francisco Pereira da Silva-Júnior; Pedro Braga-Neto; Francisca Sueli Monte; Veralice Meireles Sales de Bruin
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

5.  Levodopa and the progression of Parkinson's disease.

Authors:  Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

6.  Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.

Authors:  Olivier Rascol; David J Brooks; Amos D Korczyn; Peter P De Deyn; Carl E Clarke; Anthony E Lang; Mona Abdalla
Journal:  Mov Disord       Date:  2006-11       Impact factor: 10.338

Review 7.  Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R Pahwa; S A Factor; K E Lyons; W G Ondo; G Gronseth; H Bronte-Stewart; M Hallett; J Miyasaki; J Stevens; W J Weiner
Journal:  Neurology       Date:  2006-04-11       Impact factor: 9.910

8.  Impact of the motor complications of Parkinson's disease on the quality of life.

Authors:  Stéphane Chapuis; Lemlih Ouchchane; Olivier Metz; Laurent Gerbaud; Franck Durif
Journal:  Mov Disord       Date:  2005-02       Impact factor: 10.338
  8 in total
  6 in total

1.  Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Authors:  Manfred Gerlach; Jürgen Beck; Peter Riederer; Maarten van den Buuse
Journal:  J Neural Transm (Vienna)       Date:  2011-01-28       Impact factor: 3.575

Review 2.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

3.  Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.

Authors:  Lawrence W Elmer; Jorge L Juncos; Carlos Singer; Daniel D Truong; Susan R Criswell; Sotirios Parashos; Larissa Felt; Reed Johnson; Rajiv Patni
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

4.  Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Authors:  Stuart H Isaacson; Stanley Fahn; Rajesh Pahwa; Caroline M Tanner; Alberto J Espay; Claudia Trenkwalder; Charles H Adler; Rajiv Patni; Reed Johnson
Journal:  Mov Disord Clin Pract       Date:  2018-02-23

5.  Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Authors:  Wolfgang Oertel; Karla Eggert; Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Claudia Trenkwalder; Reinhard Ehret; Jean Philippe Azulay; Stuart Isaacson; Larissa Felt; Mary Jean Stempien
Journal:  Mov Disord       Date:  2017-08-21       Impact factor: 10.338

6.  Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.

Authors:  Robert A Hauser; Daniel E Kremens; Lawrence W Elmer; David L Kreitzman; Ryan R Walsh; Reed Johnson; Robert Howard; Jack T Nguyen; Rajiv Patni
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.